A5006933759- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Cardiac tumors and thrombi
- Management of metastatic bone disease
- Bone Tumor Diagnosis and Treatments
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Musculoskeletal synovial abnormalities and treatments
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Gastrointestinal disorders and treatments
- Soft tissue tumor case studies
- Metastasis and carcinoma case studies
- Advanced MRI Techniques and Applications
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Colorectal and Anal Carcinomas
- Breast Cancer Treatment Studies
- Neurofibromatosis and Schwannoma Cases
- Reconstructive Surgery and Microvascular Techniques
- Cardiac Imaging and Diagnostics
University College London
2015-2024
University College London Hospitals NHS Foundation Trust
2009-2024
University College Hospital
2015-2024
The Maria Sklodowska-Curie National Research Institute of Oncology
2016
International Institute for Molecular Oncology
2016
National Health Service
2016
Helios Klinikum Emil von Behring
2015
Helios Hospital Berlin-Buch
2015
Klinikum Stuttgart
2015
Royal National Orthopaedic Hospital NHS Trust
2015
BackgroundFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as sarcoma.MethodsThe GeDDiS trial was a randomised controlled phase 3 done in 24 UK hospitals one Swiss Group Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed of Trojani grade 2 3, disease progression before enrolment, no previous chemotherapy any cancer. Patients...
These guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices British Sarcoma Group and are intended to provide framework for multidisciplinary care patients with soft tissue sarcomas. The published by European Society Medical Oncology (ESMO) National Comprehensive Cancer Network (NCCN) used as basis discussion adapted according clinical practice local requirements. Note was also taken Institute Health Clinical Excellence (NICE) improving...
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.
Abstract BACKGROUND: Pigmented villonodular synovitis (PVNS) (also known as diffuse‐type giant cell tumor) and tenosynovial tumors (TGCT) are rare, usually benign neoplasms that affect the synovium tendon sheaths in young adults. These driven by overexpression of colony stimulating factor‐1 (CSF1). CSF1 is expressed a minority tumor cells, which, turn attract non‐neoplastic inflammatory cells express receptor (CSF1R) through paracrine effect. METHODS: Imatinib mesylate (IM) blocks CSF1R,...
The efficacy of palliative chemotherapy was investigated in a large group patients with advanced soft-tissue sarcomas (STS) treated on routine protocols.Patients STS who had first-line for and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, gastrointestinal stromal tumors excluded study.In all, 488 (242 male, 246 female) fulfilled study criteria....
Novelli M, Rossi S, Rodriguez‐Justo Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn P C W, Sciot R, Van Glabbeke Verweij J, Blay J Y, Hohenberger Flanagan A & Dei Tos (2010) Histopathology 57 , 259–270 DOG1 and CD117 are the antibodies of choice in diagnosis gastrointestinal stromal tumours Aims: The histopathological (GIST) is typically made based on a combination clinical morphological features supported by immunohistochemistry studies. aim this study was to examine staining...
BACKGROUND The objectives of this study were to provide sunitinib patients with gastrointestinal stromal tumor (GIST) who otherwise unable obtain it and collect broad safety efficacy data from a large population advanced GIST after imatinib failure. (ClinicalTrials.gov identifier NCT00094029). METHODS Imatinibresistant/ intolerant received on an initial dosing schedule 50 mg daily in 6‐week cycles (4 weeks treatment, 2 off treatment). Tumor assessment frequency was according local practice,...
Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues. Gastrointestinal stromal tumour (GIST) is the commonest STS and arises within wall of gastrointestinal (GI) tract. While most GISTs occur stomach they do all parts GI As with other STS, it important that managed by expert teams, to ensure consistent optimal treatment, as well recruitment clinical trials, ongoing accumulation further knowledge disease. The development appropriate guidance, an experienced panel...
Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue that unresponsive to chemotherapy. Cediranib, tyrosine-kinase inhibitor, has shown substantial activity in ASPS non-randomised studies. The Cediranib Soft Part Sarcoma (CASPS) study was designed discriminate the effect of cediranib from intrinsically indolent nature ASPS.In this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants 12 hospitals UK (n=7), Spain (n=3), and Australia (n=2). Patients were...
Cancer genetics has to date focused on epithelial malignancies, identifying multiple histotype-specific pathways underlying cancer susceptibility. Sarcomas are rare malignancies predominantly derived from embryonic mesoderm. To identify specific mesenchymal cancers, we performed whole-genome germline sequencing 1644 sporadic cases and 3205 matched healthy elderly controls. Using an extreme phenotype design, a combined rare-variant burden ontologic analysis identified two sarcoma-specific...
There are neither prospective data nor agreement on the optimal routine follow-up procedures in patients treated for soft tissue sarcoma of limb. Data 174 consecutive with a limb undergoing by oncologists at single centre from 2003 to 2009 were included this analysis. The rate and site recurrence mode detection analysed. Outcome was assessed. Eighty-two (47%) experienced relapse any type. Isolated local occurred 26 synchronous pulmonary metastases five patients. Local recurrences detected...
These guidelines have been developed in order to provide an overview and a set of broad-based key recommendations for the management patients with bone sarcomas UK. They taken into consideration most up-to-date scientific literature along recent by European Society Medical Oncology. The principles NICE guidance on both “improving outcomes sarcomas” children young people cancer” incorporated. As care evolves, it is acknowledged that these will need updating. are pain or palpable mass should...
Abstract Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated long term effects of IM in TGCT. We conducted an international multi-institutional retrospective assess activity IM: data was collected anonymously from individual...
10500 Background: Standard first-line treatment of locally advanced/metastatic soft tissue sarcoma (STS) is Dox. GemDoc has activity in STS and used relapsed after failure at least one line chemotherapy. Our aim was to compare with Dox as STS. Methods: Patients (pts) from 24 UK sites 1 Swiss site were randomised receive 6 cycles 75 mg/m2 intravenously (IV) day every 3 weeks, or Gem 675 IV days 8 Doc weeks (wks). Pts had STS, Trojani grade 2 3, disease progression prior enrolment, no...